7 research outputs found
Contribution of the 8-Methoxy Group to the Activity of Gatifloxacin against Type II Topoisomerases of Streptococcus pneumoniae
The inhibitory activities (50% inhibitory concentrations [IC(50)s]) of gatifloxacin and other quinolones against both DNA gyrase and topoisomerase IV of the wild-type Streptococcus pneumoniae IID553 were determined. The IC(50)s of 10 compounds ranged from 4.28 to 582 μg/ml against DNA gyrase and from 1.90 to 35.2 μg/ml against topoisomerase IV. The inhibitory activity against DNA gyrase was more varied than that against topoisomerase IV among fluoroquinolones. The IC(50)s for DNA gyrase of the 8-methoxy quinolones gatifloxacin and AM-1147 were approximately seven times lower than those of their 8-H counterparts AM-1121 and ciprofloxacin, whereas the IC(50)s for topoisomerase IV were 1.5 times lower. Moreover, the IC(50) ratios (IC(50) for DNA gyrase/IC(50) for topoisomerase IV) of gatifloxacin, AM-1147, and moxifloxacin, which possess 8-methoxy groups, were almost the same. The 8-methoxy quinolones showed higher antibacterial activity and less mutant selectivity against IID553 than their 8-H counterparts. These results suggest that the 8-methoxy group enhances both target inhibition, especially for DNA gyrase, leading to potent antipneumococcal activity and dual inhibition against both DNA gyrase and topoisomerase IV in the bacterial cell
Target Preference of 15 Quinolones against Staphylococcus aureus, Based on Antibacterial Activities and Target Inhibition
The antibacterial activities and target inhibition of 15 quinolones against grlA and gyrA mutant strains were studied. The strains were obtained from wild-type Staphylococcus aureus MS5935 by selection with norfloxacin and nadifloxacin, respectively. The antibacterial activities of most quinolones against both mutant strains were lower than those against the wild-type strain. The ratios of MICs for the gyrA mutant strain to those for the grlA mutant strain (MIC ratio) varied from 0.125 to 4. The ratios of 50% inhibitory concentrations (IC(50)s) of quinolones against topoisomerase IV to those against DNA gyrase (IC(50) ratios) also varied, from 0.177 to 5.52. A significant correlation between the MIC ratios and the IC(50) ratios was observed (r = 0.919; P < 0.001). These results suggest that the antibacterial activities of quinolones against the wild-type strain are involved not only in topoisomerase IV inhibition but also in DNA gyrase inhibition and that the target preference in the wild-type strain can be anticipated by the MIC ratios. Based on the MIC ratios, the quinolones were classified into three categories. Type I quinolones (norfloxacin, enoxacin, fleroxacin, ciprofloxacin, lomefloxacin, trovafloxacin, grepafloxacin, ofloxacin, and levofloxacin) had MIC ratios of <1, type II quinolones (sparfloxacin and nadifloxacin) had MIC ratios of >1, and type III quinolones (gatifloxacin, pazufloxacin, moxifloxacin, and clinafloxacin) had MIC ratios of 1. Type I and type II quinolones seem to prefer topoisomerase IV and DNA gyrase, respectively. Type III quinolones seem to target both enzymes at nearly the same level in bacterial cells (a phenomenon known as the dual-targeting property), and their IC(50) ratios were approximately 2
LpxC Inhibitors: Design, Synthesis, and Biological Evaluation of Oxazolidinones as Gram-negative Antibacterial Agents
Herein we report
a scaffold-hopping approach to identify a new
scaffold with a zinc binding headgroup. Structural information was
used to give novel oxazolidinone-based LpxC inhibitors. In particular,
the most potent compound, <b>23j</b>, showed a low efflux ratio,
nanomolar potencies against <i>E. coli</i> LpxC enzyme,
and excellent antibacterial activity against <i>E. coli</i> and <i>K. pneumoniae</i>. Computational docking was used
to predict the interaction between <b>23j</b> and <i>E.
coli</i> LpxC, suggesting that the interactions with C207 and
C63 contribute to the strong activity. These results provide new insights
into the design of next-generation LpxC inhibitors
Oxabicyclooctane-Linked Novel Bacterial Topoisomerase Inhibitors as Broad Spectrum Antibacterial Agents
Bacterial resistance is eroding the
clinical utility of existing
antibiotics necessitating the discovery of new agents. Bacterial type
II topoisomerase is a clinically validated, highly effective, and
proven drug target. This target is amenable to inhibition by diverse
classes of inhibitors with alternative and distinct binding sites
to quinolone antibiotics, thus enabling the development of agents
that lack cross-resistance to quinolones. Described here are novel
bacterial topoisomerase inhibitors (NBTIs), which are a new class
of gyrase and topo IV inhibitors and consist of three distinct structural
moieties. The substitution of the linker moiety led to discovery of
potent broad-spectrum NBTIs with reduced off-target activity (hERG
IC<sub>50</sub> > 18 μM) and improved physical properties.
AM8191
is bactericidal and selectively inhibits DNA synthesis and <i>Staphylococcus aureus</i> gyrase (IC<sub>50</sub> = 1.02 μM)
and topo IV (IC<sub>50</sub> = 10.4 μM). AM8191 showed parenteral
and oral efficacy (ED<sub>50</sub>) at less than 2.5 mg/kg doses in
a <i>S. aureus</i> murine infection model. A cocrystal structure
of AM8191 bound to <i>S. aureus</i> DNA-gyrase showed binding
interactions similar to that reported for GSK299423, displaying a
key contact of Asp83 with the basic amine at position-7 of the linker